Skip to main content
. Author manuscript; available in PMC: 2019 Feb 15.
Published in final edited form as: Cancer Res. 2017 Dec 11;78(4):1017–1030. doi: 10.1158/0008-5472.CAN-17-1318

Figure 3. Identification of miRNAs differentially expressed in VMF-resistant A375 melanoma cells.

Figure 3

(A) qPCR validation of miRNA expression changes between parental and VMF-resistant cells (n=5). (B, C) A375-VR or parental A375 cells were incubated for the indicated times in the absence (B) or presence of VMF (1.3 μM) (C), and subsequently subjected to qPCR analyses for miRNA expression (n=3). (D) Dose-response analyses of miRNA expression in A375 and A375-VR cells cultured for 48 h in the absence (Ctrl) or presence of the indicated concentrations (0.1 to 1.3 μM) of vemurafenib. miRNA expression was significantly upregulated, ***p<0.001, **p<0.01, *p<0.05, or significantly reduced, ΔΔΔp<0.001, ΔΔp<0.01, Δp<0.05. (E) Cells were incubated for 48 h in medium (Ctrl) or in the presence of TMT (4 nM), SCH772984 (50 nM), triciribine (5 μM), NSC23766 (10 μM), and subsequently analyzed by qPCR for expression of the shown miRNAs (n=3-4).